- Bellicum Pharmaceuticals press release ( NASDAQ: BLCM ): Q2 GAAP EPS of -$0.13 beats by $0.56 .
- Cash and cash equivalents and restricted cash totaling $34.7M as of June 30, 2022.
- “We have continued to make progress with our patient enrollment efforts in the BPX-601 and BPX-603 trials and I am pleased with our execution,” said Rick Fair, President and Chief Executive Officer. “Our team remains focused on generating Phase 1 data that highlight the potential advantages of our GoCAR-T technology.”
For further details see:
Bellicum Pharmaceuticals GAAP EPS of -$0.13 beats by $0.56